63:, Switzerland. It was produced in several countries and the content was derived from 65 qualitative interviews with patients in the UK, Italy and Netherlands. The initial version of the measure was produced in UK English and it was then translated for the Netherlands, Italy, Germany, France and the US. A Spanish version was then later developed. Further tests were implemented to validate the measure and it was administered to 300 patients in each country to finalize the instrument.
289:
Whalley, D.; McKenna, S.P.; Dewar, A.L.; Erdman, R.A.; Kohlmann, T.; Niero, M.; Cook, S.A.; Crickx, B.; Herdman, M.J.; Frech, F.; Van Assche, D. (2004). "A new instrument for assessing quality of life in atopic dermatitis: international development of the
Quality of Life Index for Atopic Dermatitis
242:
Lambert, J.; Bostoen, J.; Geusens, B.; Bourgois, J.; Boone, J.; De Smedt, D.; Annemans, L. (January 2011). "A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results".
50:
for patients over the age of 16 with a maximum score of 25 and is restricted to yes or no answers. Higher scores on the QoLIAD indicate a greater negative influence that the disease has on quality of life.
359:
Bostoen, J.; Bracke, S.; De Keyser, S.; Lambert, J. (November 2012). "An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial".
89:
The QoLIAD has also been utilized to assess the effectiveness of new treatments of atopic dermatitis. This includes studies looking into educational intervention, topical
17:
86:
The QoLIAD has been translated into seven languages other than UK English. They include German, Spanish and
Japanese.
71:
32:
115:
78:(Italy), C.H.U Bichat (France), 3D Health Research (Spain) and Novartis Pharmaceuticals Corporation (USA).
402:
Lax, Stephanie J; Harvey, Jane; Axon, Emma; Howells, Laura; Santer, Miriam; et al. (March 2022).
505:
460:
194:
Ashcroft, D.M.; Chen, L.C.; Garside, R.; Stein, K.; Williams, H.C. (2007). Ashcroft, Darren M (ed.).
75:
155:
384:
315:
268:
67:
66:
The institutions involved in the development of the QoLIAD are: Galen
Research (United Kingdom),
441:
423:
376:
307:
260:
221:
36:
472:
431:
415:
368:
299:
252:
211:
203:
167:
127:
90:
40:
461:"PSK6 BELGIAN DRUG UTILISATION STUDY OF ELIDEL® IN ROUTINE PRACTICE IN ATOPIC DERMATITIS"
216:
195:
436:
403:
477:
172:
132:
116:"Psk6 Interpreting Scores on the Quality of Life Index for Atopic Dermatitis (Qoliad)"
499:
372:
303:
47:
459:
Lecomte, P.; Lambert, J.; Degreef, H.; Lesaffre, E.; De Backer, M. (November 2006).
388:
319:
272:
419:
333:
207:
94:
404:"Strategies for using topical corticosteroids in children and adults with eczema"
18:
Knowledge talk:Articles for creation/Quality of Life Index for Atopic
Dermatitis
156:"Psn12 Quality-Of-Life in Patients Suffering from Atopic Dermatitis in Germany"
114:
Meads, D.M.; McKenna, S.P.; Doward, L.C.; Hampson, N.; McGeown, C. (May 2005).
256:
427:
154:
Ehlken, B.; Kugland, B; Schramm, B; Quednau, K; Berger, K. (November 2003).
445:
380:
311:
264:
225:
60:
59:The QoLIAD was developed in 2004 and funded by
8:
408:The Cochrane Database of Systematic Reviews
29:Quality of Life Index for Atopic Dermatitis
196:"Topical pimecrolimus for eczema (Review)"
476:
435:
284:
282:
237:
235:
215:
171:
131:
200:Cochrane Database of Systematic Reviews
106:
7:
245:Archives of Dermatological Research
361:The British Journal of Dermatology
25:
373:10.1111/j.1365-2133.2012.11113.x
304:10.1111/j.1365-2133.2004.05783.x
35:which measures the impact that
31:(QoLIAD) is a disease specific
420:10.1002/14651858.CD013356.pub2
292:British Journal of Dermatology
208:10.1002/14651858.CD005500.pub2
39:(AD) has on a given patient's
1:
478:10.1016/S1098-3015(10)63408-0
173:10.1016/S1098-3015(10)62005-0
133:10.1016/S1098-3015(10)62870-7
522:
257:10.1007/s00403-010-1082-z
72:University of Greifswald
33:patient reported outcome
76:University of Verona
334:"Measures Database"
70:(The Netherlands),
338:Galen-Research.com
68:Erasmus University
61:Novartis Pharma AG
82:International use
37:atopic dermatitis
16:(Redirected from
513:
490:
489:
487:
485:
480:
456:
450:
449:
439:
399:
393:
392:
367:(5): 1025–1031.
356:
350:
349:
347:
345:
340:. Galen Research
330:
324:
323:
286:
277:
276:
239:
230:
229:
219:
191:
185:
184:
182:
180:
175:
151:
145:
144:
142:
140:
135:
111:
46:It is a 25-item
21:
521:
520:
516:
515:
514:
512:
511:
510:
496:
495:
494:
493:
483:
481:
465:Value in Health
458:
457:
453:
414:(3): CD013356.
401:
400:
396:
358:
357:
353:
343:
341:
332:
331:
327:
288:
287:
280:
241:
240:
233:
202:(4): CD005500.
193:
192:
188:
178:
176:
160:Value in Health
153:
152:
148:
138:
136:
120:Value in Health
113:
112:
108:
103:
91:corticosteroids
84:
57:
41:quality of life
23:
22:
15:
12:
11:
5:
519:
517:
509:
508:
498:
497:
492:
491:
451:
394:
351:
325:
298:(2): 274–283.
278:
231:
186:
166:(6): 787–788.
146:
126:(3): 331–332.
105:
104:
102:
99:
83:
80:
56:
53:
24:
14:
13:
10:
9:
6:
4:
3:
2:
518:
507:
504:
503:
501:
479:
474:
470:
466:
462:
455:
452:
447:
443:
438:
433:
429:
425:
421:
417:
413:
409:
405:
398:
395:
390:
386:
382:
378:
374:
370:
366:
362:
355:
352:
339:
335:
329:
326:
321:
317:
313:
309:
305:
301:
297:
293:
285:
283:
279:
274:
270:
266:
262:
258:
254:
250:
246:
238:
236:
232:
227:
223:
218:
213:
209:
205:
201:
197:
190:
187:
174:
169:
165:
161:
157:
150:
147:
134:
129:
125:
121:
117:
110:
107:
100:
98:
96:
92:
87:
81:
79:
77:
73:
69:
64:
62:
54:
52:
49:
48:questionnaire
44:
42:
38:
34:
30:
19:
482:. Retrieved
468:
464:
454:
411:
407:
397:
364:
360:
354:
342:. Retrieved
337:
328:
295:
291:
251:(1): 57–63.
248:
244:
199:
189:
177:. Retrieved
163:
159:
149:
137:. Retrieved
123:
119:
109:
95:pimecrolimus
88:
85:
65:
58:
45:
28:
26:
506:Dermatology
471:(6): A268.
290:(QoLIAD)".
74:(Germany),
55:Development
484:28 October
344:28 October
179:28 October
139:28 October
101:References
428:1469-493X
500:Category
446:35275399
389:11139439
381:22709422
320:23271179
312:14996098
273:20817434
265:20842368
226:17943859
217:10043871
437:8916090
444:
434:
426:
387:
379:
318:
310:
271:
263:
224:
214:
385:S2CID
316:S2CID
269:S2CID
486:2013
442:PMID
424:ISSN
412:2022
377:PMID
346:2013
308:PMID
261:PMID
222:PMID
181:2013
141:2013
93:and
27:The
473:doi
432:PMC
416:doi
369:doi
365:167
300:doi
296:150
253:doi
249:303
212:PMC
204:doi
168:doi
128:doi
502::
467:.
463:.
440:.
430:.
422:.
410:.
406:.
383:.
375:.
363:.
336:.
314:.
306:.
294:.
281:^
267:.
259:.
247:.
234:^
220:.
210:.
198:.
162:.
158:.
122:.
118:.
97:.
43:.
488:.
475::
469:9
448:.
418::
391:.
371::
348:.
322:.
302::
275:.
255::
228:.
206::
183:.
170::
164:6
143:.
130::
124:8
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.